RFP
TGTX icon

Root Financial Partners’s TG Therapeutics TGTX Stock Holding History

Root Financial Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.02K Buy
91
+42
+86% +$1.25K ﹤0.01% 2154
2025
Q4 		$1.46K Buy
49
+43
+717% +$1.4K ﹤0.01% 2039
2025
Q3 		$217 Buy
+6
New +$198 ﹤0.01% 2206

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Root Financial Partners's TGTX Position: Q1 2026 in Review

Root Financial Partners increased its TG Therapeutics (TGTX) stake by 86% in Q1 2026, buying an estimated $1.25K and bringing the position to 91 shares worth $3.02K. The position accounts for ﹤0.01% of the portfolio, ranked #2154.

Root Financial Partners first reported a position in TGTX in Q3 2025 and has held it in 3 quarters since. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Root Financial Partners held 91 shares of TG Therapeutics worth $3.02K as of Q1 2026.
  • Root Financial Partners bought 42 TG Therapeutics shares in Q1 2026, an estimated $1.25K.
  • TG Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q1 2026, its #2154 holding.
  • Root Financial Partners first reported a position in TG Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Root Financial Partners's 13F filing for Q1 2026, filed 24 Apr 2026.